<DOC>
	<DOCNO>NCT00326911</DOCNO>
	<brief_summary>Eligible patient metastatic pancreatic cancer treat dual agent monoclonal antibody consist cetuximab bevacizumab alone combination gemcitabine</brief_summary>
	<brief_title>Cetuximab Bevacizumab With Without Gemcitabine Treat Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>The patient provide sign write informed consent . The patient ≥18 year age . The patient histologically cytologicallyconfirmed pancreatic adenocarcinoma amenable curative treatment surgery document suspect extrapancreatic metastasis . The patient either ( ) measurable disease define Response Evaluation Criteria Solid Tumors Version 1.0 ( RECIST ) ( b ) nonmeasurable disease elevate baseline CA199 level ( ≥2 x upper limit normal [ ULN ] ) . The patient 's Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . The patient adequate hematologic function define absolute neutrophil count ( ANC ) ≥1500/mm3 platelet count ≥100,000/mm3 obtain within 2 week prior first dose study medication . The patient adequate hepatic function define total bilirubin ≤2.0 mg/dL transaminase ≤5.0 x ULN obtain within 2 week prior first dose study medication . The patient adequate renal function define serum creatinine ≤2.0 x ULN urine dipstick proteinuria ≤1+ obtain within 2 week prior first dose study medication . If urine dipstick ≥2+ , 24hour urine protein must demonstrate &lt; 1000 mg protein 24 hour allow participation study . Urinalysis also acceptable . If patient fulldose anticoagulation therapy ( eg , warfarin low molecular weight [ LMW ] heparin ) , follow criterion must meet : The patient inrange International Normalized Ratio ( [ INR ] usually 2 3 ) stable dose oral anticoagulant stable dose LMW heparin The patient active bleed pathological condition carry high risk bleeding ( e.g. , tumor involve major vessel know varix ) If patient fulldose anticoagulation therapy , follow criterion must meet : The patient adequate coagulation function define INR ≤1.5 The patient partial thromboplastin ( PTT ) ≤ULN obtain within 2 week prior first dose study medication If woman , patient agrees use accepted effective method contraception ( hormonal barrier method , abstinence ) prior study entry duration study . If male sexually active , patient agrees use effective contraception . The patient accessible treatment followup . Patients enrol trial must treat participate center . Endocrine tumor lymphoma pancreas Known brain metastasis Prior therapy epidermal growth factor receptor ( EGFR ) inhibitor vascular endothelial growth factor ( VEGF ) inhibitor Prior chemotherapy , hormonal therapy , radiation therapy advance pancreatic cancer , patient receive chemotherapy and/or radiation therapy adjuvant set eligible long adjuvant therapy complete &gt; 6 month prior Concurrent malignancy nonmelanomatous skin cancer carcinoma situ cervix Concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiotherapy , chemoembolization , target therapy Ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation History arterial thrombotic event within 9 month History uncontrolled hypertension ( &gt; 150/100 mmHg ) stable regimen antihypertensive therapy History significant bleeding event upper low gastrointestinal bleeding within 9 month History gastrointestinal perforation within 12 month Serious nonhealing wound ulcer , bone fracture , major surgical procedure 28 day If woman , pregnant lactate An employee investigator study center well family member employee</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>